Circulating microvesicles for predicting post-stroke cardiovascular outcomes


  • High levels of circulating endothelial (EMV) and platelet-derived microvesicles (PMV) in the acute phase following ischemic stroke could be a biomarker of increased long-term risk of recurrent stroke, myocardial infarction or all-cause mortality.

Why this matters

  • Circulating microvesicles are shed into the bloodstream by different cell types in response to inflammation. For example, EMV are released by inflamed endothelial cells lining the blood vessels and are biomarker of endothelial dysfunction. It is thought that circulating microvesicles could be used to predict cardiovascular risk.

  • EMV levels are associated with stroke severity and lesion volume in ischemic stroke and other types of microvesicles – for example, platelet-derived and monocytic – are increased in the acute post-stroke phase.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.